Avid Bioservices Inc (CDMO)

[Protector]

jbainseky, read the complete post, not just the first line. I am not talking about the June 2013 PII results, they are of NO interest in this conversation about what Bavituximab's performance in the PIII (SUNRISE) could be.

This line of conversation started when you wrote that I expected Bavituximab in PIII to outperform Bavituximab in PII and that you did not know that the OS MOS was 12 months.

I told you that I am looking at the Sept 7th 2012 results because, after the salvaging of the dose switching and Dr. Brekkens public confirmation at NYAS, PPHM knows that are the results that must be used for TRIAL DESIGN (even if PPHM filed only a conservative 60% improvement to the FDA vs 113% in Sept 7th 2012 - they called it CONSERVATIVE for a reason!). If you doubt my word on NYAS, there were OTHER posters of this board present at that NYAS conference that, if they are still alive :), can confirm this. The question was ask by an older guy from Charles Schwab and Brekken responded after Shan and King, who where standing at the side, nodded that he could disclose.

So I don't make anything up, you are referring to a result set that I don't use and for which I explained, TWO TIMES NOW, WHY I don't use it. Furthermore you seem not to have as much information collected first-hand in the field which possibly explains why you do not make the difference between the REAL results of Spet 7th 2012 and the ADMINISTRATIVE FILED CONSERVATIVE results for the EOPII meeting with the FDA which are reflected in the Jun 2013 text that you quoted.

FFor the TRIAL DESIGN of SUNRISE PPHM was free to use the results of SEPT 7th 2012.

These ones from the Chicago Conference.

OS MOS of 1+3mg/Kg arms is 12.1 months.